Clinical trial recruitment starts with site and protocol design

Tell us about your project

Please reach out to us about your project and see how we can help you accomplish your goals.

We value your privacy and will never share your contact information

Please note that submissions without a valid business email address or business phone number may not receive a timely response

Healthcare Solutions

If you're in healthcare, you owe it to yourself to learn how you can make your everyday business processes more efficient and save money at the same time. We can help in automating many of your routine and repetitive tasks, including Patient Engagement surveys.

Contact us to learn more

Transportation Solutions

If you're in the transportation business, you can automate many of your routine tasks like package notifications, surveys, collection calls and more. Improve your customer satisfaction by extending your service hours without extending your costs.

Connect with us to learn more

Why representation outcomes trace back to where you place sites, who the protocol screens in, and how participants can respond

Clinical trial recruitment is commonly treated as an outreach problem: run ads, call lists, train sites, and hope the eligible people respond. What actually determines who enrolls is shaped long before outreach begins by where the trial sits, who the protocol screens in or out, and what communication pathways are available to potential participants. Recent reporting that structural drivers matter more than outreach intensity is a reminder that representation failures are often baked into the design.

For trial operations, this means if you only measure recruitment effort and not the access your design creates, you will repeatedly miss representation goals. The result is predictable sample bias, slower enrollment, and expensive mid-study fixes.

Where design choices quietly filter out participants

Several common early decisions reduce access without anyone noticing. Site location is the most visible. Research centers cluster in particular geographies, so distance and travel cost create a selection effect for rural, low-income, and some Indigenous communities. Eligibility rules do the same work invisibly: restrictive lab ranges or narrow comorbidity exclusions remove otherwise willing patients. The chosen data-collection mode matters too. Web or app-only approaches leave behind people who prefer voice, lack smartphones, or have limited English proficiency.

These problems interact. A trial with urban sites, narrow labs, and an app-only follow-up will systematically exclude patients who live farther away, who have different baseline labs, and who rely on phone contact. When those exclusions line up with race, ethnicity, age, or socioeconomic status, the trial’s enrolled population will diverge from the disease demographics it claims to represent.

What fixing it later actually costs

Correcting these problems after enrollment starts is expensive. Adding a new site in underserved territory requires contracts, site initiation, training, and monitoring. Broadening eligibility after screen failures are already high may raise safety and endpoint concerns. Introducing a new communication channel mid-study complicates data flow, consent documentation, and audit trails.

The operational pressure shows up in three ways executives will recognize. First, enrollment slows and budgets creep because outreach is being asked to solve a structural problem. Second, screen-failure rates rise and attrition grows as the study encounters participants whose baseline characteristics conflict with the protocol’s assumptions. Third, corrective changes trigger regulatory and monitoring work that eats time and attention.

Practical early checks operations teams should require

  • Compare the demographics of the target disease against the planned enrollment catchment, and ask whether the site network covers underserved geographies.
  • Review eligibility criteria for ranges and exclusions that could be broadened safely without changing the scientific question.
  • Map preferred communication channels for the intended population and plan phone-first or multilingual options where needed.

These checks do not guarantee perfect representation, but they spotlight predictable failure modes before they become costly. A simple map of travel distance to available sites, paired with a quick survey about language and device access, often reveals underserved pockets that outreach alone will not fix. For baseline reality checks you can also consult public trial registries to see geographic gaps for similar studies.

Operational design that reduces bias and preserves endpoints

The operational pattern that tends to work is inclusion by design: choose sites and enrollment criteria with representation in mind, and bake flexible, per-participant communication into the protocol so each enrollee is reached on their own timeline. That means planning for phone-first patient-reported outcome (PRO) collection where appropriate, offering surveys in participants’ preferred languages, and designing follow-ups so they fit each participant’s day zero rather than a fixed calendar schedule.

Language access is the part most programs underestimate. Multilingual delivery and translation of open-ended feedback turn a number into usable insight and reduce dropout among non-English speakers. When participant engagement must hold up across the study lifecycle, operations teams should review how follow-ups, missed-visit outreach, and retention communications will function in practice. A helpful overview is at clinical trial participant engagement that holds up.

The other practical piece is per-participant timelines. Enrollment is rolling, and each person’s week-2 or month-3 check-in falls on a different calendar day. Systems that treat measurements as per-person events rather than batch tasks reduce missed data and protect endpoints. That design also limits the need for mid-study fixes that can threaten statistical integrity.

Phone-first PRO collection and secure messaging reach participants who would never open an email survey, and they preserve higher capture rates among older adults and rural participants. When these approaches are considered early, the study can avoid the tradeoff between scale and representativeness. For practical examples of phone-based PRO collection and how it fits into trial operations, see our overview of PROMIS and phone/SMS survey delivery.

The work that leads to better representation is a set of design choices made before enrollment: where you place sites, how you set eligibility, and how you plan to collect follow-up data. Getting those choices right reduces downstream cost and ethical risk, and it makes recruitment metrics meaningful rather than misleading. If representation is a goal, treat it as a design constraint, not an outreach target to be fixed later.

Related coverage: Beyond Outreach: Structural Drivers of Representation in Clinical Trials — Applied Clinical Trials Online